Top 20 Biotech Venture Capital Deals of 2009

Welcome to our annual report on the top biotech venture capital deals. 2009 was an incredibly difficult year for biotech companies to raise venture funding, as the financial crisis caused firms to become more cautious with their money. But for companies with groundbreaking technology and exciting programs, there was still money to be had. 

With the help of data provided by the National Venture Capital Association, we've put together a list that examines some of the most promising companies in the field, and details technology that garnered investor attention even as many other companies in the industry folded. Take a look at this list of the top 20 U.S. companies that raised big money in 2009. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.